С

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

)	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
---	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average I	burden									

Estimated average burden	
hours per response:	0.5

1. Name and Address of Reporting Person [*] MJALLI ADNAN M M			2. Issuer Name and Ticker or Trading Symbol SIGA TECHNOLOGIES INC [SIGA]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
				X	Director	Х	10% Owner			
				4	Officer (give title		Other (specify			
(Last) C/O TRANSTE		·	3. Date of Earliest Transaction (Month/Day/Year) 07/30/2009		below)		below)			
	HALL OAKS	PARKWAY, SUITE								
110			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	/idual or Joint/Group	Filing ((Check Applicable			
(Street)				X	Form filed by One	e Repor	ting Person			
HIGH POINT	NC	27265			Form filed by Mor Person	e than (One Reporting			
(City)	(State)	(Zip)								

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Transaction Disposed Of (D Code (Instr.				5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150. 4)
Common Stock, par value \$0.0001 per share ("Common Stock")	07/30/2009		S		1,000,000 ⁽¹⁾	D	\$6.24	2,472,222	Ι	by TransTech Pharma, Inc. ⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		ransaction of code (Instr. Derivative		of Expiration Date Oerivative Securities Acquired A) or Disposed of (D) Instr. 3, 4		tion of Expi Istr. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		Expiration Date		Amount of		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						

Explanation of Responses:

1. On July 30, 2009, TransTech Pharma, Inc. sold 1,000,000 shares of Common Stock in a privately negotiated transaction to MacAndrews & Forbes LLC.

2. The shares of Common Stock and the warrants are beneficially owned by TransTech Pharma, Inc. The reporting person is the President, Chief Executive Officer and a director of TransTech Pharma, Inc. The reporting person disclaims beneficial ownership of the securities beneficially owned by TransTech Pharma, Inc. except to the extent of his pecuniary interest therein.

Remarks:

<u>Adnan M. M. Mjalli</u>

** Signature of Reporting Person Date

08/03/2009

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.